

#### 1 March 2022

# Submission of comments on

# ICH Q9 – R1 Draft – Quality Risk Management (EMA/CHMP/ICH/24235/2006)

Please note that these comments and the identity of the sender will be published unless a specific justified objection is received. When completed, this form should be sent to the European Medicines Agency electronically, in Excel format (not PDF), to the following address: ICH@ema.europa.eu

All the cells with an asterisk (\*) should be filled in prior to completing the columns "Comment and rationale" and/or "Proposed changes / recommendation". For more details on how to use this template please refer to the tab "Manual for commenter".

Name of organisation or individual*	Line from* (line Nr or 0 for general comment)	Line to* (line Nr or 0 for general comment)	Section number	Comment and rationale (to go to next line within the same cell use Alt + Enter)	Proposed c (if applicab text change
ECA Foundation / European QP Association	0	0	General	The promotion of a science-based approach to risk management relying on knowledge management according to Q10 is really appreciated. - Such an approach requires objective risk assessment.	
ECA Foundation / European QP Association	0	0	General	The terminology change "hazard identification" replacing "risk identification" is appreciated and it is even considered being an improvement.	
ECA Foundation / European QP Association	0	0	General	The scope extension to the supply chain and widely considering the "operational capability" of the organisation/company is seen as an important topic that should allow for better consideration of this criteria in other regulatory documents, e.g. EU / PIC/S GMP Annex 11.	
				This scope extension shall be the trigger by regulated user organisation to apply a holistic approach to Quality Risk Management, covering all relevant aspects impacting <i>appropriate and continued supplies of that medicinal product</i> , see European Directive 2001/83/EC, Article 81 (excerpt): The holder of a marketing authorisation for a medicinal product and the distributors of the said medicinal product actually placed on the market in a Member State shall, within the limits of their responsibilities, ensure appropriate and continued supplies of that medicinal product to pharmacies and persons authorised to supply medicinal products so that the needs of patients in the Member State in question are covered	
ECA Foundation / European QP Association	0	0	General	Since it is mentioned at several places that decisions should be "objective" rather than "subjective", objectivity and subjectivity shall be introduced and explained at the beginning of the document. Such an addition would have the merit of clarifying the discussion on this point in the rest of the document.	
ECA Foundation / European QP Association	0	0	General	Recommendation for the supporting training material on Q9 >>>	Content prop - Presentation - Explanation means: > Method > Availab evaluation - Reminder t greatly from these are pro-



Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000



An agency of the European Unior



Name of organisation or individual*	Line from* (line Nr or 0 for general comment)	Line to* (line Nr or 0 for general comment)	Section number	Comment and rationale (to go to next line within the same cell use Alt + Enter)	Proposed c (if applicat text chang
ECA Foundation / European QP Association	0	0	General	Wording: this draft uses "formality" when "formalism" would be more appropriate regarding the necessary documentation effort of the risk management activities; see occurences at lines: #53, #56, #57, #79, #248, #251, #252, #253, #254, #256, #260, #266, #270, #274, #276, #277, #281, #289, #290, #299, #304, #320, #321, #322, #395, #522	Please repla
ECA Foundation / European QP Association	0	0	General	With the technological developments of the last 15 years leading to an increasing digitalisation of processes on the one hand, and the increasing regulatory focus on data integrity on the other, it is necessary that these topics are included in the overall scope of Quality Risk Management. Mentioning explicitly these topics would help to secure that the cross-functional teams performing QRM will be adequately populated with the corresponding SME.	
ECA Foundation / European QP Association	0	0	General	In the following remarks, IT and OT are mentioned; for clarity here are the corresponding definitions: - IT: Information Technology - OT: Operational Technology; i.e. IT for process automation, covering industrial control systems (manufacturing and facility) and laboratory equipment. See https://en.wikipedia.org/wiki/Operational_technology	
ECA Foundation / European QP Association	43	43	1	and computerized systems is important. See comment at line #370	
ECA Foundation / European QP Association	98	98	4,1	It is crucial for securing the "objectivity" of the decisions that the risk management activities are carried out by an "interdisciplinary team". See comment at line #295	Quality risk undertaken
ECA Foundation / European QP Association	251	251	5,1	See the above general remark about "formality" vs "formalism".	Please repla (incl. headin
ECA Foundation / European QP Association	288	289	5,1	See the above general remark about "formality" vs "formalism".	Use of a trai to a higher f
ECA Foundation / European QP Association	295	295	5,1	See comment at line #98	A cross func
ECA Foundation / European QP Association	303	305	5,2	Effective risk-based decision making begins with determining the level of effort, formality and documentation that should be applied during the quality risk management process. The statement is not correct. "Effective risk-based decision making" is the result (the consequence) of the risk management effort.	Effective risk level of effor during the q level of effor the quality r
ECA Foundation / European QP Association	305	308	5,2	Wording: in the particular context "outcome" would be more appropriate than "output".	The outcome decisions in those hazard residual risk quality risk r
ECA Foundation / European QP Association	376	376	6	Since "distribution" is explicitly mentioned in the document scope (section 2, line #69), the item at line #376 shall be improved accordingly.	Supply Chai

changes / recommendation
ble - to be used if you want to propose specific
les)

place "formality" with "formalism".

sk management activities are usually<del>, but not always,</del> en by interdisciplinary teams.

lace "formality" with "formalism" in the whole section 5.1 lings).

rained quality risk management facilitator may be integral r formal<del>ity</del> process.

nctional team might not be necessary.

risk-based decision making begins with determining the fort, formality and documentation that should be applied e quality risk management process is the result of the ffort, formalism and documentation that are applied during y risk management process.

mes of quality risk management activities include n relation to what hazards exist, the risks associated with ards, the risk controls required, the acceptability of the sk after risk controls, the communication and review of < management activities and outcomes.

nain Control, including distribution

Name of organisation or individual*	Line from* (line Nr or 0 for general comment)	Line to* (line Nr or 0 for general comment)	Section number	Comment and rationale (to go to next line within the same cell use Alt + Enter)	Proposed cl (if applicab text change
ECA Foundation / European QP Association	370	376	6	Since " <i>digitalization and emerging technologies</i> " are explicitly mentioned in the document introduction (section 1, line #40), within the scope of Quality Risk Management, IT and OT infrastructure robustness as well as cybersecurity shall be considered as well. Today, a weak IT/OT infrastructure can highly jeopardize the manufacturing, QC, and supply chain processes as well as the overall business capability of the regulated organisation. The experience showed already the vital impact such IT/OT infrastructure and computerized systems can have on the operational capability of a pharmaceutical company (see NotPetya ransomware case, June 2017, at MSD, Reckitt Benckiser, Beiersdorf,). Likewise, IT/OT robustness as well as cybersecurity shall be added in Annex II section 4 (see comment at lines #769-777) since these topics represent the Achilles' heel of every regulated user organisation.	<ul><li>Producti</li><li>Laborato</li></ul>
ECA Foundation / European QP Association	405	410	6	Based on the comment related to lines 370-376, the possible weaknesses and vulnerability of supporting process control systems and applications shall be explicitly mentioned. Alternatively, this topic could be addressed in a dedicated section, since similar recommendations are necessary for the other processes, such as laboratory processes, supply chain, quality management.	A robust faci control and r includes suita manufacturir multiple fact such as out-o maintenance error. Risks t as well as th automation, Nevertheless infrastructure and automat possibly repr jeopardizing
ECA Foundation / European QP Association	412	420	6	<ul> <li>Following the above comments regarding the necessity to take IT &amp; OT robustness into account within the scope of Quality Risk Management, it is necessary to explicitly mention the data supporting or related to the outsourced activities.</li> <li>Such an improvement is perfectly aligned with the requirements stated in EU / PIC/S GMP Part I, Chapter 7 and in WHO TRS 996, Annex 5, Chapter 7.</li> <li>The regulated organisation must be aware that the integrity of the data related to the outsourced activities is a vital necessity. As such, these data - and implicitly the supporting IT and OT infrastructures at contractor side - must become part of the overall Quality Risk Management acitivities.</li> </ul>	Quality syste supply chain oversight of by risk asses effective mod A successful appropriate of such collabor and to review activities). W and safety of enhanced rev 2.7 of ICH Q new supply of perform a fur

# changes / recommendation able - to be used if you want to propose specific ges)

- for industry operations and activities (see Annex II): opment;
- y, equipment and utilities, including automation; als management;
- ction;
- atory control and stability testing;
- ging and labeling;
- / Chain Control, including distribution;
- rting IT & OT infrastructures and applications.

acility infrastructure (including the supporting process d monitoring systems) can facilitate reliable supply; it uitable equipment and well-designed facilities for uring and packaging. Robustness can be affected by actors, such as an aging facility (including software aging at-of-support or poorly supported software), insufficient ace or an operational design that is vulnerable to human as to supply can be reduced by addressing these factors, through use of modern technology, such as digitalization, n, isolation technology, amongst others.

ess consideration must be given to the IT and OT ures, systems, and applications enabling digitalization nation, but being themselves subject to vulnerability and epresenting weaknesses for the processes and ng the related electronic data.

stem governance includes assuring the acceptability of in partners over the product lifecycle. Approval and of outsourced activities and material suppliers is informed essments, effective knowledge management, and an nonitoring strategy for supply chain partner performance. ul manufacturing partnership is strengthened by e communication and collaboration mechanisms (Note: poration and communication include the ability to secure iew the data supporting or related to the outsourced When substantial variability is identified in the quality of supplied materials or in the services provided, review and monitoring activities are justified (See Section Q10). In some cases, it may be necessary to identify a y chain entity (e.g. a pre-qualified backup option) to function.

Name of organisation or individual*	Line from* (line Nr or 0 for general comment)	Line to* (line Nr or 0 for general comment)	Section number	Comment and rationale (to go to next line within the same cell use Alt + Enter)	Proposed of (if application text change)
ECA Foundation / European QP Association	475	475	7	Some definitions provided in the previous version have been forgotten: - Risk Management - Risk Reduction - Risk Review - Severity - Stakeholder - Trend The suppresion of "Risk Identification" is correct, since it is replaced by "Hazard Identification".	Risk Manag The systema procedures, communicat Risk Reduc Actions take the severity Risk Review Review or m process com about the ris Severity: A measure of Stakeholder also be stak stakeholders authority, an Trend: A statistical
ECA Foundation / European QP Association	684	684	Annex II.1	Following the above comments regarding the necessity to take IT & OT robustness into account within the scope of Quality Risk Management, it is necessary to explicitly mention this topic as one of the criteria to be considered by defining extent and frequency of audits resp. inspections.	variable(s).  • Robustr • Digital i infrastructur 
ECA Foundation / European QP Association	769	777	Annex II.4	The current text needs some refreshing for better reflecting the current field reality.	Computerise To select the computation modular, str To determin • identific • selectio • code re • the exte • black • regre • funct • reliabilit and signatur • procedu
ECA Foundation / European QP Association	786	787	Annex II.5	To determine whether it is appropriate to use material under quarantine (e.g., for further internal processing); Even if this statement was already provided in the current version, the formulation contradicts EU / PIC/S GMP Part I, Chapter 5.34: Only starting materials which have been released by the Quality Control department and which are within their retest period should be used.	To determin <del>quarantine</del> ( (e.g., for fu
ECA Foundation / European QP Association	844	844	Annex II.9	Typo since "program" is spelled out differently in other sections.	To establish assure relial

# changes / recommendation able - to be used if you want to propose specific ges)

## agement:

matic application of quality management policies, es, and practices to the tasks of assessing, controlling,

cating and reviewing risk.

## uction:

ken to lessen the probability of occurrence of harm and ity of that harm.

#### iew:

monitoring of output/results of the risk management onsidering (if appropriate) new knowledge and experience risk.

e of the possible consequences of a hazard. der:

dual, group or organization that can affect, be affected by, re itself to be affected by a risk. Decision makers might akeholders. For the purposes of this guideline, the primary ers are the patient, healthcare professional, regulatory and industry.

al term referring to the direction or rate of change of a

stness of a company's quality risk management activities; I maturity and robustness of the supporting IT & OT ure and systems;

ised systems and computer controlled equipment the design of <del>computer hardware and software</del> onal resources and supporting IT/OT infrastructures (e.g.,

- structured, fault tolerance, (cyber)security measures); nine the extent of validation, e.g.,
- fication of critical performance parameters;
- ion of the requirements and design;
- review;
- xtent of testing and test methods, such as:
- ck box tests, white box tests, source code review;
- ression tests, integration tests;
- ctional and performance tests;
- ility integrity (according to ALCOA+) of electronic records tures;
- dural controls.

ine whether it is appropriate to use material undere under which conditions material can be released for use urther internal processing);

sh equipment and facility maintenance programmes that iable facility and equipment performance;

Name of organisation	Line	Line	Section	Comment and rationale	Proposed
or individual*	from* (line Nr or 0 for general comment)	to* (line Nr or 0 for general comment)	number	(to go to next line within the same cell use Alt + Enter)	(if applica text chang
ECA Foundation / European QP Association		855	Annex II.9	It might be meaningful to move this section at line #834 (before the section "Manufacturing Process Variation and State of Control")	
					-
					ļ

changes / recommendation
ble - to be used if you want to propose specific
jes)
